A study to examine the impact of blockade of the renin-angiotensin system on vascular compliance measurements in subjects with type 2 diabetes mellitus complicated by nephropathy
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Irbesartan (Primary) ; Ramipril (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 23 Sep 2009 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials record.
- 21 Jul 2006 New trial record.